Home Healthcare Pharmaceuticals Scleroderma Therapeutics Market

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Type (Localized Scleroderma, Systemic Sclerosis, Diffuse Sclerosis, Others), By Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogs, Others), By Route of Administration (Parenteral, Oral, Topical), By End-User (Hospitals, Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR6790DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Scleroderma Therapeutics Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Localized Scleroderma
    2. Systemic Sclerosis
    3. Diffuse Sclerosis
    4. Others
  2. Scleroderma Therapeutics Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Immunosuppressors
    2. Phosphodiesterase 5 inhibitors – PHA
    3. Endothelin Receptor Antagonists
    4. Prostacyclin Analogs
    5. Others
  3. Scleroderma Therapeutics Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Parenteral
    2. Oral
    3. Topical
  4. Scleroderma Therapeutics Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Clinics
    3. Others
  5. Regional Scleroderma Therapeutics Market
    1. North America
      1. North America Scleroderma Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
      2. North America Scleroderma Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Immunosuppressors
        2. Phosphodiesterase 5 inhibitors – PHA
        3. Endothelin Receptor Antagonists
        4. Prostacyclin Analogs
        5. Others
      3. North America Scleroderma Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. North America Scleroderma Therapeutics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Others
      5. U.S.
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      6. Canada
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
    2. Europe
      1. Europe Scleroderma Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
      2. Europe Scleroderma Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Immunosuppressors
        2. Phosphodiesterase 5 inhibitors – PHA
        3. Endothelin Receptor Antagonists
        4. Prostacyclin Analogs
        5. Others
      3. Europe Scleroderma Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. Europe Scleroderma Therapeutics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Others
      5. U.K.
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      6. Germany
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      7. France
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      8. Spain
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      9. Italy
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      10. Russia
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      11. Nordic
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      12. Benelux
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      13. Rest of Europe
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
    3. APAC
      1. APAC Scleroderma Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
      2. APAC Scleroderma Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Immunosuppressors
        2. Phosphodiesterase 5 inhibitors – PHA
        3. Endothelin Receptor Antagonists
        4. Prostacyclin Analogs
        5. Others
      3. APAC Scleroderma Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. APAC Scleroderma Therapeutics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Others
      5. China
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      6. Korea
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      7. Japan
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      8. India
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      9. Australia
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      10. Taiwan
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      11. South East Asia
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      12. Rest of Asia-Pacific
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
    4. Middle East and Africa
      1. Middle East and Africa Scleroderma Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
      2. Middle East and Africa Scleroderma Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Immunosuppressors
        2. Phosphodiesterase 5 inhibitors – PHA
        3. Endothelin Receptor Antagonists
        4. Prostacyclin Analogs
        5. Others
      3. Middle East and Africa Scleroderma Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. Middle East and Africa Scleroderma Therapeutics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Others
      5. UAE
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      6. Turkey
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      7. Saudi Arabia
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      8. South Africa
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      9. Egypt
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      10. Nigeria
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      11. Rest of MEA
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
    5. LATAM
      1. LATAM Scleroderma Therapeutics Market By Type 2022-2034 (USD MILLION/ Units)
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
      2. LATAM Scleroderma Therapeutics Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Immunosuppressors
        2. Phosphodiesterase 5 inhibitors – PHA
        3. Endothelin Receptor Antagonists
        4. Prostacyclin Analogs
        5. Others
      3. LATAM Scleroderma Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. LATAM Scleroderma Therapeutics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Others
      5. Brazil
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      6. Mexico
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      7. Argentina
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      8. Chile
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      9. Colombia
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
      10. Rest of LATAM
        1. Localized Scleroderma
        2. Systemic Sclerosis
        3. Diffuse Sclerosis
        4. Others
        5. Immunosuppressors
        6. Phosphodiesterase 5 inhibitors – PHA
        7. Endothelin Receptor Antagonists
        8. Prostacyclin Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospitals
        14. Clinics
        15. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.